This is certainly much more credible than naysayers using uneducated and misleading information to attack Gale.
It is certainly much better than those one-line barkers.
He does not know why. He is just barking like a mad dog and does not even know why he is barking!
I really enjoy this healthy debate. This is a good way to keep this message board constructive.
You need to prove why there is a resistance.
You must be Lucifer, as soon as you call for a fall, Gale's price will drop?
Your tactics is not working. Pretty soon, you pay-master (stock manipulator) fire you and then you have to go back to a street corner and beg for spare change to feed yourself and your family, if you have a family at all.
Have a lousy and miserable weekend.
There is no place for pure "speculators" here.
I do not think you owned any Gale shares to sell. You are using insidious suggestions to get people to sell.
Not a chance, toxic basher!
Not matter what, negative writers and bashers must ask themselves these questions.
Understand the real science of NeuVax from Christopher Davis and you will have confidence to buy and hold Gale shares!
It looks like the more toxin the bashers pour on Gale, the more Gale's share price is moving up!
It appears that bashers may have something to contribute.
Training our own immune system (cancer vaccines) to fight cancers is the biotechnological platform of the future. Gale's NeuVax is the beginning to revolutionize the entire breast cancer treatment approach.
Let us hold our horses for a minute. I have been the most avid supporter of RXII based on its "gene silencing" technology, its "self-delivery system", its capability to treat many serious disease other than anti-scarring, it good management and its association with OPKO and Teva.
RXI-109 Phase 1 was based on a very small number of patients. The results were impressive and they gave a modest lift to RXII's share price. Granted that Phase 2 is based on larger number of patients, would the good results for this Phase 2 lift it to $13 and beyond?
I agree that if Phase 3 produce impressive results and obtains FDA approval, RXII's share price will shoot way up. By how much? It is hard to say. Yet for a potential $3 billion market, it may be around $40 per share.
Correct me if I am wrong. RXII is still very much under investors' radar screen. A lot of us was hoping that it will move beyond $5 after the up-listing. Look where we are today.
I think the investment community needs to know and wake up to the huge potential of "gene silencing" and RXII's "self-delivery system" before significant price rise.
That day will come. Yet it may not be so soon!
There are no pumpers here. There are good and honest Gale investors who offer verifiable facts to share with each other.
Funny, we never see or hear bashers who can offer some verifiable facts to back up their toxic messages.
Bend down gayboy. We like to stick a baseball bat right through your butt.
All of the positive fundamentals of Gale have not changed. Abstral is going to report outstanding sales, Gale's financial position will be improved, NeuVax Phase 3 will be fully enrolled by mid-2014, NeuVax Phase 2b (NeuVax + Herceptin) will product excellent results.
Gale-301 will demonstrate good results and Gale-401 will rapidly obtain FDA approval with a peak sales of $200 million.
Good heavens, the toxic bashers keep barking about insiders selling ??? Stale poison, is it not ???